Jacqualyn “Jackie” Fouse was one of the top executives at Celgene, beloved by Wall Street and credited with helping to oversee a period of strong revenue growth and stock performance for the biotech company. Then, last year, she “retired,” after reportedly being passed over for the top job.
Now Fouse has a shot to run her own show.
On Tuesday, Cambridge-based Agios Pharmaceuticals said it had hired Fouse, already a board member, as its chief executive, effective Feb. 1. Current Agios CEO David Schenkein is retiring up to become the biotech’s executive chairman.
About the Author Reprints
